Please login to the form below

Not currently logged in
Email:
Password:

non-alcoholic steatohepatitis drugs

This page shows the latest non-alcoholic steatohepatitis drugs news and features for those working in and with pharma, biotech and healthcare.

Roche enters NASH race with deal to buy Jecure

Roche enters NASH race with deal to buy Jecure

Company joins Novartis, Pfizer and others in nascent market. Roche has joined the melee of pharma companies trying to claim a share of the market for non-alcoholic steatohepatitis (NASH) drugs, ... Roche is playing catch-up with a host of other companies

Latest news

  • Allergan buys two NASH drug developers in one day Allergan buys two NASH drug developers in one day

    More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics.  Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH) ... pipeline. . The acquisition puts Allergan in a race

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics